What Archeus Technologies does

Archeus Technologies is a clinical-stage, privately held biopharmaceutical company founded in 2016 and headquartered in Madison, Wisconsin, that develops differentiated small-molecule radiopharmaceutical therapies (RPTs) for hard-to-treat cancers. The company's pipeline is built around a proprietary NM600 tumor-targeting platform — a small-molecule chemistry platform developed through a long-standing collaboration with the University of Wisconsin-Madison — that enables selective delivery of therapeutic and diagnostic radioisotopes to tumor tissue. Its lead clinical programs include ARC-706 (a yttrium-90 radiopharmaceutical therapy designed for combination with immune checkpoint inhibitors across multiple oncology indications), ARC-166 (a yttrium-86 PET companion diagnostic for imaging-guided dosing of ARC-706), and ART-101 (a PSMA-targeting small molecule for imaging and treatment of metastatic castration-resistant prostate cancer, positioned as a differentiated alternative to FDA-approved PSMA agents with lower salivary gland uptake). The FDA cleared Investigational New Drug applications for all three programs in June 2025, and first patient dosings occurred in December 2025 (ART-101) and May 2026 (ARC-706/ARC-166).

Archeus operates a clinical-development-driven business model with no commercial revenue. The company runs Phase 1 trials through academic medical center partnerships — principally UW Carbone Cancer Center and BAMF Health, a vertically integrated theranostics platform — and co-develops its PSMA program under a collaboration with the Wisconsin Alumni Research Foundation (WARF). Its intended monetization path is licensing, royalty, and commercial sale of approved radiopharmaceutical therapies, with distribution expected through specialty pharmacies and hospital systems post-approval. The company has 1-10 employees, is led by CEO Evan Sengbusch (former president of Phoenix, sold to SHINE Technologies), and is supported by a leadership and advisory team drawn from UW-Madison faculty, former executives of Nordion, Jubilant, Plus Therapeutics, Bracco, and IBA Molecular, and the inventor of ProHance (Mike Tweedle). Multiple granted patents protect the NM600 platform and alkylphosphocholine analog chemistry, with co-founder Jamey Weichert listed as co-inventor on more than 50 patents in cancer imaging and therapy agents.

The company's strategic positioning emphasizes theranostics (paired therapeutic and diagnostic agents), combination radiotherapy-plus-immunotherapy, and improved tolerability relative to incumbent PSMA radioligands. As of mid-2026 the company is pre-revenue, with three Phase 1-enabling INDs cleared, two active Phase 1 trials, and a recently expanded clinical leadership team — typical of an early clinical-stage oncology company approximately 3-5 years from potential pivotal-stage data.

Name

Archeus Technologies

Legal name

Archeus Technologies

Website

https://archeustech.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Archeus Technologies is a clinical-stage radiopharmaceutical company developing differentiated small-molecule therapies and companion diagnostics for hard-to-treat cancers, with three FDA-cleared IND programs (ARC-706, ARC-166, ART-101) in Phase 1 trials targeting metastatic and prostate cancers.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG)

Keywords

• Radiopharmaceutical therapies
• Oncology drug development
• Companion diagnostics
• Cancer therapeutics
• Radiopharmaceutical agents

Headquarters

HQ city

Madison

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Radiopharmaceutical Therapy Pipeline: Archeus Technologies is a clinical-stage company developing a pipeline of differentiated radiopharmaceutical therapy agents. Revenue will be generated through commercialization of novel cancer therapies pending regulatory approval.
2. Companion Diagnostics: The company develops companion diagnostic assets alongside therapeutic products, enabling personalized treatment selection and dosing optimization for radiopharmaceutical therapies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Archeus Technologies is a clinical-stage radiopharmaceutical company developing differentiated small-molecule radiopharmaceutical therapies (RPTs) and companion diagnostics for hard-to-treat cancers. Its pipeline includes ARC-706 (yttrium-90 therapy paired with the ARC-166 yttrium-86 PET companion diagnostic for combination use with immune checkpoint inhibitors) and ART-101 (a PSMA-targeting agent for prostate cancer), all built on the proprietary NM600 tumor-targeting platform developed through its long-standing collaboration with the University of Wisconsin-Madison.

Product overview

Archeus Technologies develops differentiated radiopharmaceutical therapies (RPTs) for hard-to-treat cancers using a theranostic approach combining therapeutic agents with companion diagnostics. The portfolio includes: ARC-706 (yttrium-90 therapeutic) with companion diagnostic ARC-166 (yttrium-86 PET imaging), and ART-101 (PSMA-targeting agent for prostate cancer). All products leverage the proprietary NM600 tumor-targeting platform technology. The company operates a clinical-stage pipeline with multiple Phase 1 trials initiated for various cancer indications.

Differentiator

Problem solved

Functional benefit

Products and services

• ARC-706 Small-molecule radiopharmaceutical therapy (RPT) using yttrium-90 (Y-90), a therapeutic beta-emitting isotope, leveraging the proprietary NM600 tumor-targeting platform. Developed for combination use with validated immune checkpoint inhibitor (ICI) therapies across a range of oncology indications to augment anti-tumor immune response. Currently in Phase 1 clinical development for metastatic cancer patients.
• ARC-166 Companion diagnostic using yttrium-86 (Y-86) PET isotope for dosimetry, patient selection, and imaging-guided dosing to determine specific dose ranges for ARC-706 therapy. Developed for oncology patient stratification and personalized treatment planning.
• ART-101 Novel receptor-based small-molecule radiopharmaceutical therapy targeting prostate-specific membrane antigen (PSMA) for imaging and treatment of prostate cancer. Demonstrated higher tumor uptake and retention with lower normal tissue and salivary gland uptake compared to FDA-approved PSMA-targeting agents in preclinical studies. Radiolabeled with Indium-111 for diagnostic imaging. Currently in Phase 1 development for metastatic castration-resistant prostate cancer.

Quantifiable outcome

• ARC-706 at specific dose ranges based on imaging significantly increases response rate and durability of responses to immune checkpoint inhibitor therapies in preclinical studies
• +1 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and major.

• Wisconsin Alumni Research Foundation (WARF)coreStrategic or Co-development Partner · 2 December 2025Collaboration agreement with WARF, the designated patent and licensing organization for the University of Wisconsin–Madison. WARF provides significant development support for ART-101, the company's PSMA-targeting prostate cancer therapy. WARF Accelerator improves commercialization potential through industry engagement and proof-of-concept milestones.
• BAMF HealthmajorStrategic or Co-development Partner · 2 December 2025Clinical trial partnership with BAMF Health, the world's first vertically integrated platform for intelligence-based precision medicine. BAMF serves as principal investigator site for Phase 1 clinical trial of ART-101 in metastatic castration-resistant prostate cancer patients. BAMF's nationwide platform enables rapid initiation and completion of novel clinical trials.
• University of Wisconsin–Madison (UW)coreStrategic or Co-development PartnerLong-standing strategic collaboration with UW, a global leader in radiopharmaceuticals and theranostics. This partnership enables Archeus privileged access to leading radiochemistry, imaging, dosimetry, and analytical capabilities. The collaboration supports preclinical research, clinical translation, and development of the company's pipeline of radiopharmaceutical therapies.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novartis: Novartis commercializes Pluvicto (177Lu-PSMA-617), the FDA-approved PSMA-targeted radioligand therapy that directly competes with Archeus's ART-101 in metastatic castration-resistant prostate cancer. Novartis also has a broader radioligand pipeline (lutathera, etc.) making it the dominant incumbent in the radiopharmaceutical oncology space Archeus targets.
• Lantheus Holdings: Lantheus develops and commercializes PSMA-targeted diagnostic imaging agents (PYLARIFY) used to identify candidates for PSMA radioligand therapy. As the dominant PSMA imaging player, Lantheus is a direct comparable in the theranostic workflow that Archeus's ARC-166 companion diagnostic targets, and shares the same end-customer radiopharma centers.
• RayzeBio (acquired by Bristol Myers Squibb): RayzeBio was a clinical-stage radiopharmaceutical company developing actinium-225-based radiopharmaceuticals for solid tumors, acquired by BMS in early 2024 for $4.1B. Closely comparable to Archeus in stage, approach (targeted radionuclide therapy), and likely exit trajectory as a strategic acquisition target.
• Point Biopharma (acquired by Eli Lilly): Point Biopharma was a clinical-stage radiopharmaceutical company developing PSMA-targeted and other radioligand therapies, acquired by Lilly in 2023 for $1.4B. It represents the most direct comparable to Archeus's stage and approach, validating the M&A appetite for clinical-stage radiopharma assets while raising the competitive bar.
• Plus Therapeutics: Plus Therapeutics is a clinical-stage radiopharmaceutical company developing targeted radiotherapies for CNS cancers and other solid tumors. Particularly relevant as Norman LaFrance, Archeus's Chair of Advisory Board, was previously Plus's CMO — and Plus's smaller, late-clinical-stage profile is a realistic comp for Archeus's likely trajectory.
• Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with approved PSMA imaging agent Illuccix and a broad theranostic pipeline across prostate cancer, renal cell carcinoma, and other solid tumors. Comparable to Archeus as a radiopharma-focused oncology company pursuing paired imaging/therapy strategies.
• Fusion Pharmaceuticals (acquired by AstraZeneca): Fusion was a clinical-stage radioconjugate company developing targeted alpha therapies, acquired by AstraZeneca in 2024 for $2.4B. Comparable to Archeus in combining targeting platforms with therapeutic radioisotopes, and another data point on big-pharma M&A appetite for clinical-stage radiopharma platforms.

Broad incumbents

• Curium: Curium is one of the largest dedicated radiopharmaceutical manufacturers globally, supplying diagnostic and therapeutic nuclear medicine products worldwide. Comparable as an incumbent in the same end-market Archeus will ultimately sell into, with established radiopharma manufacturing and distribution capabilities.
• Bayer: Bayer commercializes Xofigo (radium-223), the first approved alpha-emitting radiopharmaceutical for prostate cancer, and has ongoing radioligand therapy development through its broader pharma portfolio. As a large incumbent with established radiopharma manufacturing and commercial reach, Bayer represents the scale player Archeus would need to partner with or compete against.

Emerging players

• ITM Isotope Technologies: ITM is a privately held radiopharmaceutical company developing targeted radionuclide therapies (notably ITM-11, a 177Lu-Edotreotide PRRT candidate) and producing medical radioisotopes. Comparable as a similarly-sized clinical-stage radiopharma company pursuing theranostic approaches across multiple oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/archeus-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Archeus Technologies